Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04944134 · ClinicalTrials.gov registry record
COVID-19 Antibody Levels After Vaccines
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 71
- Enrollment target
NCT04944134: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT04944134 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 71 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04944134 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 71 participants
- Enrollment target
Study Summary
This study will measure the levels of nasal mucosal Immunoglobulin A (IgA) and blood serum IgA up to one year after COVID vaccination, as well as examining what factors might affect antibody levels in the nose. This will be done through nasal epithelial lining fluid collection and standard venipuncture.
Primary Outcome
Level of COVID-specific antibodies in the nasal mucosa
Interventions
- BIOLOGICAL COVID-19 Vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2022-04-01 |
What the finished NCT04944134 record still lists
NCT04944134 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which COVID-19 Vaccination is the first listed.
NCT04944134 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04944134 about?
NCT04944134 is a clinical study titled "COVID-19 Antibody Levels After Vaccines". This study will measure the levels of nasal mucosal Immunoglobulin A (IgA) and blood serum IgA up to one year after COVID vaccination, as well as examining what factors might affect antibody levels in the nose. This will be done through nasal epithelial lining fluid collection and standard venipunct...
What is the current status of trial NCT04944134?
This trial is currently completed. The enrollment target is 71 participants. The study started on 2021-06-09. Estimated completion is 2022-04-01.
What interventions are being tested in trial NCT04944134?
The interventions under investigation include: COVID-19 Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT04944134?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI